Co-crystal Screening: from Smart Design to Effective Experimentation

  • Application note
  • March 8, 2023
About the author

Technobis Crystallization Systems is deeply grateful to Dr. Mihaela Pop and Drd. Doriana Ungur, TeraCrystal for their help with this application note. The experimental work presented in this application note was performed in the laboratories of TeraCrystal. The AI calculations were performed at Radboud University Nijmegen and were presented in this application note with the help of Dr. Rene de Gelder and Dr. Jan Joris Devogelaer.

Learn more about creating an effective co-crystal screening protocol

Solid form selection and development is one of the key aspects of pharmaceutical research, as over 90% of all APIs on the market are approved as solid formulations. These require a thorough understanding of the solid form landscape of the API and of the crystallization process to be reliably controlled towards the desired solid form. By choosing the appropriate polymorph, salt or co-crystal of the given API, the formulation chemist can tune the physico-chemical properties of the compound, and in turn its therapeutic profile.

This application note shows that an effective co-crystal screening protocol can be defined, using the Crystal16 instrument.

Content overview:
  • Why co-crystals?
  • Co-crystal screening state-of-the-art
  • The case study of Febuxostat and its co-crystal screening with p-toluenesulfonic acid
  • Using an AI graph algorithm for co-crystal prediction
  • Co-crystal experimental screening
  • Method A: Cooling Crystallization
  • Method B: Slurry Crystallization
  • Conclusions

Download application note